Acquisition by De Verneuil Vanina of 70000 shares of Vir Biotechnology at 9.57 subject to Rule 16b-3
| VIR Stock | USD 5.11 0.01 0.20% |
Slightly above 55% of Vir Biotechnology's investor base is interested to short. The analysis of overall sentiment of trading Vir Biotechnology stock suggests that many investors are impartial at this time. Vir Biotechnology's investing sentiment overview a quick insight into current market opportunities from investing in Vir Biotechnology. Many technical investors use Vir Biotechnology stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Vir Biotechnology Officer: Evp And General Counsel. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Vir Biotechnology Fundamental Analysis
We analyze Vir Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vir Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vir Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Vir Biotechnology is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Vir Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vir Biotechnology stock to make a market-neutral strategy. Peer analysis of Vir Biotechnology could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics with similar companies.
Peers
Vir Biotechnology Related Equities
| MDGL | Madrigal Pharmaceuticals | 3.29 | ||||
| INO | Inovio Pharmaceuticals | 2.80 | ||||
| BNTX | BioNTech | 0.95 | ||||
| CVAC | CureVac NV | 0.18 | ||||
| APLS | Apellis Pharmaceuticals | 0.25 | ||||
| IOVA | Iovance Biotherapeutics | 2.83 | ||||
| CODX | Co Diagnostics | 3.85 |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.